Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
←Back to story

Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn

Financial TimesView source article

Part of story

J&J in talks to acquire eye disease biotech for up to $3.4bn

Johnson & Johnson is poised to acquire a privately held eye disease drug developer in a deal valued at up to $3.4 billion, according to the Financial Times.

Nov 15, 2026·2 sourcesWet AMDMergers & acquisitions (M&A)Macular edema treatmentMergers and acquisitionsFinancial tiesPharmaceutical IndustryBiotech innovationTexasDrug development
J&J in talks to acquire eye disease biotech for up to $3.4bn
00

Other sources for this story

Reuters

J&J looks to buy Ollin Biosciences for up to $3.4 billion, FT says | Reuters